



Nontuberculous *Mycobacteria*

4

Emilyn Costa Conceição, Maria Cristina S. Lourenço,
Rafael Silva Duarte, and Philip Noel Suffys

4.1 Introduction on the Genus *Mycobacterium*

After the first description of *Bacillus leprae* in 1875 by Hansen and the following discovery of *Mycobacterium tuberculosis* by Robert Koch in 1882, the genus finally emerged as a taxonomic group of pathogens named *Mycobacterium* as proposed by Lehmann and Neumann in 1896 [1]. The genus is composed of aerobic rod-shaped Gram-positive acid-fast microorganisms, most of them exhibiting facultative intracellular growth and having varied environmental reservoirs. Some *Mycobacterium* spp. also are associated with important well-known historical human diseases such as leprosy and tuberculosis, among others, while also being pathogenic for animals, some of them with zoonotic potential.

The use of the term “atypical acid-fast microorganisms” was introduced in 1935 to designate a mycobacterial isolate that caused human disease but could not be differentiated from *M. tuberculosis* by morphology, pigmentation, and virulence in animals [2]. Three years later, Costa Cruz isolated a fast-growing *Mycobacterium* from a human abscess that he named *M. fortuitum* [3]. A series of mycobacteria different from the *tuberculosis bacillus* started to be recognized as etiologic agents of human diseases, including *M. marinum* 1926 [4], *M. ulcerans* (1950) [5], *M.*

E. C. Conceição · M. C. S. Lourenço

Laboratório de Bacteriologia e Bioensaios em Micobactérias, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

Laboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

R. S. Duarte

Laboratório de Micobactérias, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

P. N. Suffys (✉)

Laboratório de Bacteriologia e Bioensaios em Micobactérias, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

intracellulare (initially named as *Nocardia intracellaris* in 1949 and later on renamed as *M. intracellulare* in 1965) [6], *M. kansasii* (1953) [7], and *M. scrofulaceum* (1956) [8], as main examples [9, 10].

It is known for decades that natural habitats of NTM are aquatic and soil environments [11]. The majority of *Mycobacterium* species have no impact on human health and occasionally, as opportunists, are responsible for human infections. However, some species are both environmental and pathogenic, while some are obligatory pathogenic. Contamination probably occurs through aerosolization or aspiration of water and/or soil particles and through exposure to traumatized skin and is generally not transmitted person to person. Therefore, it is important to identify the species that cause an infection in cases where the symptoms are sufficient to support sample collection [12–14].

4.1.1 The Taxonomy of Mycobacteria

Considering the present version of the List of Prokaryotic Names with Standing in Nomenclature (LPSN) database (available at <http://www.bacterio.net/m/mycobacterium.html>), a total of 192 validly published taxa are included in the genus *Mycobacterium*, including species and subspecies that are distributed in three major groups: (i) the *Mycobacterium tuberculosis* complex (MTBC), (ii) the distinct species *Mycobacterium leprae*, and (iii) the nontuberculous mycobacteria (NTM), also called mycobacteria other than the MTBC. Traditionally, mycobacteria have been divided into rapidly (RGM) and slowly growing mycobacteria (SGM), the former needing less than 7 days for visible colony formation on solid culture media, the latter more than 7.

Through the years, the systematic taxonomy of this genus has evolved considerably based on grouping of phenotypic properties, analysis of chemotaxonomic characteristics, and sequence comparison of the 16S rRNA; of the 65-kDa heat-shock protein; of the genes *recA*, *rpoB*, *gyrA*, *gyrB*, *secA1*, *sodA*, *tuf*, and *smgB*; of the tmRNA; and of the 16S-23S rRNA intergenic spacer (ITS) region, performing a multilocus sequence analysis approach of concatenating several gene sequences, by interspecific DNA-DNA hybridization technique and/or, most recently, by genomic comparison.

Recent studies have suggested a new taxonomic classification and phylogenomic structure for mycobacteria based on datasets of genes/proteins from the genomes of different species. In 2018, Gupta et al. [15] suggested the redefinition of mycobacterial taxa based on amino acid insertions or deletions of fixed lengths within a specific position at a conserved region, named conserved signature indels (CSIs). These clade-specific marker gene sequences were proposed as a better definition of relationships among mycobacteria for determining the vertical inheritance and phylogenetic tree building as performed on datasets of concatenated protein sequences and proposed to relocate the mycobacterial taxa into five distinct genera: *Mycobacterium*, *Mycobacteroides*, *Mycolicibacillus*, *Mycolicibacter*, and *Mycolicibacterium*. However, Tortoli et al. [16] and most of the researchers in this study field preferred

Table 4.1 Nomenclature for the main *Mycobacterium* species as summarized by Tortoli et al. [16]

Classical nomenclature	Nomenclature adjustment proposed by Tortoli et al. [16] ^a	Nomenclature according to Gupta et al. [15]
<i>Mycobacterium abscessus</i> subsp. <i>abscessus</i>		<i>Mycobacteroides abscessus</i> subsp. <i>abscessus</i>
<i>Mycobacterium abscessus</i> subsp. <i>bolletii</i>		<i>Mycobacteroides abscessus</i> subsp. <i>bolletii</i>
<i>Mycobacterium abscessus</i> subsp. <i>massiliense</i>		<i>Mycobacteroides abscessus</i> subsp. <i>massiliense</i>
<i>Mycobacterium avium</i> subsp. <i>avium</i>	<i>Mycobacterium avium</i> subsp. <i>avium</i> var. <i>avium</i>	
<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i>		
<i>Mycobacterium avium</i> subsp. <i>silvaticum</i>	<i>Mycobacterium avium</i> subsp. <i>avium</i> var. <i>silvaticum</i>	
<i>Mycobacterium chelonae</i> subsp. <i>chelonae</i>		<i>Mycobacteroides chelonae</i>
<i>Mycobacterium chelonae</i> subsp. <i>bovis</i>		
<i>Mycobacterium chelonae</i> subsp. <i>gwanakae</i>	<i>Mycobacterium chelonae</i> subsp. <i>bovis</i>	
<i>Mycobacterium fortuitum</i> subsp. <i>fortuitum</i>	<i>Mycobacterium fortuitum</i>	<i>Mycolicibacterium fortuitum</i>
<i>Mycobacterium fortuitum</i> subsp. <i>acetamidolyticum</i>	<i>Mycobacterium fortuitum</i>	<i>Mycolicibacterium fortuitum</i>
<i>Mycobacterium gordonae</i>		
<i>Mycobacterium immunogenum</i>		<i>Mycobacteroides immunogenum</i>
<i>Mycobacterium intracellulare</i> subsp. <i>intracellulare</i>		
<i>Mycobacterium intracellulare</i> subsp. <i>chimaera</i>		<i>Mycobacterium chimaera</i>
<i>Mycobacterium intracellulare</i> subsp. <i>yongonense</i>	<i>Mycobacterium intracellulare</i> subsp. <i>chimaera</i>	
<i>Mycobacterium kansasii</i>		
<i>Mycobacterium parafortuitum</i>		<i>Mycolicibacterium parafortuitum</i>
<i>Mycobacterium smegmatis</i>		<i>Mycolicibacterium smegmatis</i>
<i>Mycobacterium tuberculosis</i> complex		<i>Mycobacterium tuberculosis</i>
<i>Mycobacterium ulcerans</i>		

^aEmpty field: nomenclature identical to the one of the first column

to use the classical nomenclature and reinforced the use of genome comparison for taxonomic classification.

By using the average nucleotide identity (ANI) and genome-to-genome distance (GGD) to analyze all the *Mycobacterium* taxa, Tortoli et al. [16] performed a detailed review and suggested specific adjustments for this genus. We detached the main species citing the classical and previously proposed nomina in Table 4.1.

4.1.2 *Mycobacterium tuberculosis* and *Mycobacterium leprae*

The two major human mycobacterioses are tuberculosis and leprosy. In 2018, ten million people fell ill of tuberculosis worldwide, killing 1.5 million of these, and 1 in 6 coinfecting with HIV [17]. Although the disease is curable, a major problem is resistance to rifampicin, evolving often to multidrug and sometimes extreme drug-resistant disease, difficult to cure with long, toxic, and expensive treatment schemes and high mortality rates.

Almost 210,000 new cases of leprosy were reported in the same year, and just like TB, these are curable with a multidrug therapy and fortunately still presenting relatively low drug resistance levels [18]. However, relapse is quite common, and the World Health Organization recommends vigilance for drug resistance. The major problems regarding this disease are late diagnosis causing physical disability and stigma.

Tuberculosis is caused by organisms belonging to the MTBC that was recently redefined as a single species [19], disease being mostly caused by *M. tuberculosis* var. *tuberculosis* and *M. tuberculosis* var. *bovis*. Leprosy is caused mostly by *M. leprae* although a second species called *M. lepromatosis* and described mainly in Mexico is causing a particular clinical form of leprosy called Lucio syndrome [20, 21]. However, both disease characteristics and geographic distribution of the latter pathogen are under active study.

During the last two decades, basically since the availability of the complete genome sequences of *M. tuberculosis* [22] and *M. leprae* [23], a large number of studies on genetic variability between strains in either species have been described. Procedures for detection of strain variability have been used in studies on definition of species, phylogeny, evolution, strain virulence, transmissibility, molecular epidemiology, drug resistance, and host response, and these topics have been covered in several good reviews. Because another review on this is beyond the objective of this chapter, we refer to some recent papers and chapter, respectively, for MTBC [24–26] and for leprosy [27].

4.2 Clinical Significance of Nontuberculous Mycobacteria

4.2.1 Disease Caused by Infection with Rapidly Growing Mycobacteria

The clinically most prevalent RGM species are *M. abscessus*, *M. chelonae*, and *M. fortuitum*. While *M. abscessus* is mostly isolated from clinical respiratory specimens, *M. fortuitum* is recovered more frequently from non-respiratory specimens. The spectrum of diseases varies among the main species of the group [28–32]:

- *M. abscessus* – Pulmonary infections, primarily associated with bronchiectasis associated with cystic fibrosis or other comorbidities, skin and soft tissue infections after cosmetic procedures or surgeries, prosthetic device infection, tenosynovitis, and osteomyelitis
- *M. chelonae* – Surgical wound infections, abscesses, keratitis, catheter-related bacteremia, and hematogenously disseminated disease in immunosuppressed individuals
- *M. fortuitum* – Skin and soft tissue infections (surgical or other traumatic lesions), chronic discharging sinuses, pulmonary infections among individuals harboring underlying pulmonary diseases, superficial lymphadenitis, prosthetic device infection, catheter-related sepsis, prosthetic valve endocarditis, and others

4.2.2 Disease Caused by Infection with Slowly Growing Mycobacteria

The major clinical syndromes associated with SGM include progressive pulmonary disease, skin and soft tissue infection due to direct inoculation, lymphadenitis, and disseminated disease in severely immunocompromised individuals by *M. avium* complex (MAC) and other NTM [31, 33]. The major clinical syndromes caused by specific species are:

- MAC – Lung diseases in HIV-negative patients, commonly associated with cystic fibrosis or middle-aged or elderly men, alcoholics, and/or smokers presenting or not underlying chronic obstructive pulmonary disease (COPD), mainly non-smoking women over 50. MAC also causes disseminated disease in severely immunocompromised patients (such as AIDS or other syndromes and upon use of immunosuppressive drugs), solitary pulmonary nodules, and hypersensitivity pneumonitis syndrome [34, 35].
- *M. avium* subsp. *paratuberculosis* (MAP) – One of the possible etiological agents of Crohn’s disease (CD) due to the characteristic tuberculous-like gastroenteritis in humans and similarities to the clinical and histopathological findings to the Johne’s disease in ruminants caused by MAP. Some studies have described the isolation of this pathogens from lymph nodes and blood of patients with CD [36].

- *M. kansasii* – Considered the second most common respiratory NTM and associated with pulmonary disease similar to tuberculosis in patients with COPD, malignancy, immunosuppressive drugs, pneumoconiosis, alcohol abuse, and/or HIV infection. This species has also been described causing disseminated disease, mainly in HIV-positive individuals [37].

Other human pathogenic SGM include *M. malmoense*, *M. marinum*, *M. simiae*, and *M. xenopi*, all associated with similar pathologies caused by other NTMs [38]. *Mycobacterium ulcerans* is particularly related to localized skin lesions progressing to extensive ulceration that may result in functional disabilities [39].

4.2.3 Considerations on Virulence and Drug Resistance

Because both virulence and drug resistance are important characteristics of NTM that can vary considerably both on a species and strain level, we mention these in this chapter as strain typing can be beneficial for the patient. Nonetheless, few data exist on direct correlation of these characteristics and characterization of NTM strains, and this in contrary to strains belonging to the MTBC (see part 1.2).

Virulence of NTM is related to their complex lipid-rich cell wall and cholesterol catabolism as a source of energy and material for the synthesis of the cell wall, proteins, and cell envelope lipoproteins responsible for bacterial adherence and their ability to form biofilms. Due to the hydrophobic nature of the cell wall, NTMs can adhere to a wide range of organic and inorganic materials, promoting as such colonization followed by either pseudo-infections or true infections. In the last few decades, there has been a report of an increase in outbreaks and diseases caused by NMT [40].

NTM are naturally resistant to a wide spectrum of antibiotics that include most TB drugs. The selective pressure imposed by other microorganisms in the soil and in the water, probably producing antimicrobials, may have led NMTs to develop innumerable resistance mechanisms to maintain their survival [41]. One of these is the thick hydrophobic double-membrane cell envelope of mycobacteria that also acts as a major permeability barrier. It was shown already in the 1990s that isolates of the then called *M. chelonae*-*M. abscessus* complex have a cell envelope about 10–20 times less permeable than that of *M. tuberculosis*. In addition, morphotypic antibiotic resistance, a phenomenon of varying degrees of drug resistance in *M. avium* which is associated with a reversible colony morphology switch (white/red on Congo red containing agar, transparent/opaque), is also attributed to changes in permeability owing to cell wall modifications [42]. Such morphologic changes might have a genetic basis and should therefore be traceable by genotyping.

Efflux pumps contribute to intrinsic drug resistance by preventing accumulation of antibiotics in the bacteria and have been mainly described for fluoroquinolones and macrolides [43]. The NTM species also induce the expression of certain genes resulting in the modification of the target binding site of the drug, the so-called inducible drug resistance, and in the case of macrolide resistance in *M. abscessus* which is mediated by the *erm(41)* gene, encoding a ribosomal methylase and

sequencing of this gene and *rrl* can predict susceptibility to clarithromycin in strains of the *M. abscessus* group [44], but this correlation does not seem to be absolute [45]. The use of strain typing for prediction of drug resistance in this group and more particular *M. abscessus* subsp. *massiliense* was demonstrated very recently by MLST and WGS [46]. The differentiation of the subspecies of the *M. abscessus* complex is indeed important because they differ in resistance to antibiotics and in treatment response.

Some genotyping tools allow simultaneous differentiation of NTM to the species and/or subspecies level and inform on drug susceptibility. GenoType NTM-DR (NTM-DR, Hain Lifescience, Nehren, Germany) line probe assay (LPA) is such a tool that enables identification of the MAC species (*M. avium*, *M. intracellulare*, and *M. chimera*), *M. chelonae*, and subspecies of the *M. abscessus* complex. The assay also allows for detection of antibiotic resistance to macrolides and aminoglycosides, including polymorphisms in the *erm* (*41*) gene.

4.3 Molecular Identification and Genotyping of Mycobacteria

Among the NTM species, only about one third is familiar to microbiologists and doctors, so their identification guides therapeutic treatment and provides clues regarding the source and route of exposure. Due to the presence of these mycobacteria in the environment, a laboratory control monitoring the growth of NMT is established following clinical and microbiological criteria known for decades. When dealing with sterile clinical specimens such as in pleural fluid, blood, cerebrospinal fluid, and tissues, among others, a single NTM is confirmative for infection, while for diagnosis of lung disease, positivity in two samples of spontaneous sputum or in one bronchoalveolar lavage sample is needed [47].

Traditional phenotypic identification procedures for NTM to the complex and sometimes species level are laborious and based on time-consuming biochemical and morphology-based tests, including their initial differentiation from the MTBC. For these tests, confluent growth is required, may take more than 20 days to achieve adequate growth, and has the limitation to be basically species-specific [48, 49]. Time for identification has much been reduced due to the development of molecular tools for NTM identification. Nevertheless, the combination of conventional and nucleic acid-based procedures is still used in many laboratories for precise diagnosis and eventual strain typing.

The molecular identification methods for diagnosis have expanded significantly, and among the most widely used are:

- The polymerase chain reaction restriction enzyme analysis of the *hsp65* gene (PRA-*hsp65* method) [50]
- Direct PCR (partial) gene sequencing with the principal target genes *16S*, *hsp65*, and *rpoB* including single target or MLST analysis [51, 52]
- Commercial rapid test based on DNA-strip technologies: INNO-LiPA Mycobacteria v2 (Fujirebio, H.U. Group, Japan); Speed-oligo® (Viracell,

Granada, Spain); GenoType CMdirect VER 1.0 (Hain Lifescience GmbH, Nehren, Germany), detecting MTBC and more than 20 clinically relevant NTM from patient specimens; and GenoType *Mycobacterium* CM VER 2.0 (Hain Lifescience GmbH, Nehren, Germany), detecting MTBC and more than 20 clinically relevant NTM from cultures

Despite being useful for identification of the species level and thus for accurate diagnosis, (most of) these methods do not discriminate within the specie and sub-species levels, with an exception of sequencing.

Hence, molecular typing procedures that characterize below the species level have been developed almost simultaneously and almost exclusively based on nucleic acid analysis (Fig. 4.1). They have been used for improving the epidemiological vigilance of mycobacteriosis based on detection of strain variability, transmission, outbreak investigations, as well as differentiation of reinfection and persistence/resistance. Through genotyping, the general idea was created that infection with NTM normally occurs from environmental sources [53]. Nonetheless, patient-to-patient transmission has been demonstrated between cystic fibrosis (CF) patients [54], and more studies are needed to evaluate the extend of such transmission events. To illustrate the major typing procedures used for NTM and their main applications, we summarize literature according to publication data in Table 4.2.




MOLECULAR TYPING METHOD	PRINCIPLE	PROCEDURE
Gel electrophoresis based		
Repetitive Extragenic Palindromic-PCR (REP-PCR)	Amplification of particular regions containing tandem repeats	
Enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR)	Amplification of particular regions containing tandem repeats 126 bp	
Random amplified polymorphic DNA (RAPD)	Digestion of chromosomal DNA by restriction enzymes	
Amplified fragment length polymorphism (AFLP)		
Pulsed field gel electrophoresis (PFGE)		
Restriction fragment length polymorphism (RFLP)		
Multilocus based		
Multilocus sequence typing (MLST)	Housekeeping genes	
Variable number of tandem repeats (VNTR)	Amplification of particular regions containing tandem repeats	
Sequencing based		
Whole genome sequencing (WGS)	DNA fragments covering the whole genome	

Fig. 4.1 The main molecular typing methods applied to Nontuberculous Mycobacteria

Table 4.2 Application and limitations of the main molecular genotyping methods applied to nontuberculous mycobacteria classified chronologically

Molecular typing method	Applications	Limitations
Repetitive extragenic palindromic-PCR (REP-PCR) [55]	Pseudo-outbreak [56], identification of source of infection [57], outbreak, and genetic diversity [58]	It is not an accurate tool for identifying organisms to the subspecies level. Low discriminatory power
Enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) [99, 100]	Genetic diversity [53, 59], distinguish <i>M. paratuberculosis</i> from other mycobacteria (IS900/ERIC-PCR) [60], study of clonality [61], genetic diversity and infection control [62], outbreak [63–65]	It has necessarily a higher DNA quality. It has difficult reproducibility once it generates many bands, and thus, it is difficult to analyze
Random amplified polymorphic DNA (RAPD) [66]	Study of clonality [61, 67, 68], genotypic diversity and infection control [62, 69], outbreak [70], differentiation of infection and pseudo-infection/pseudoendemic [71], characterization of novel specie proposal [72], genetic diversity [73], identification of source of infection [74–77], clonality [78], strain discrimination [79], pseudo-outbreak [80, 81], outbreak [82]	Lacks inter-test and interlaboratory reproducibility; potential for misinterpretation is greater than that by PFGE. There is not a universal primer; we must test a set of primers. It generates many bands, and thus, it is difficult to analyze
Amplified fragment length polymorphism (AFLP) [83]	Identification of source of infection [84, 85], molecular epidemiology [86], genetic diversity [87, 88]	It is not an accurate tool for identifying organisms to the subspecies level. Low discriminatory power
Pulsed field gel electrophoresis (PFGE)	Outbreak [63–65, 89–94] and pseudo-outbreak [95, 96], molecular epidemiology [97], novel specie proposal [72], genetic diversity [58], identification of source of infection [98–104], study of clonality [59], differentiation of relapse from reinfection [105], specie differentiation [60, 106, 107]	PFGE depends on DNA quality, and the typing results can be influenced by a method of DNA isolation, electrophoresis/running conditions [108]. Inability to type <i>M. abscessus</i> due to DNA degradation [107]. High cost of reagents compared to ERIC and RAPD [62]
Restriction fragment length polymorphism (RFLP) [109]	Genetic diversity [59, 108, 110], specie differentiation [106, 111], identification of source of infection [98, 112–115], specie identification and differentiation [116–120]	It is labor-intensive and requires a high level of operator skill
Multilocus sequence typing (MLST)	Specie identification [97, 110, 121, 122], molecular epidemiology [123], differentiation of infection from reinfection [124], phylogeny [97] and characterization of novel specie proposal (<i>Mycobacterium paraintracellulare</i> sp. nov. [125])	High cost of reagents compared to ERIC and RAPD [62]

(continued)

Table 4.2 (continued)

Molecular typing method	Applications	Limitations
Variable number of tandem repeats (VNTR) [126]	Influence of genotype [127], transmission [128, 129], genetic diversity [108, 130–134], phylogeny and association of genotypes to drug susceptibility [135–137], genotypes associated with clinical aspects [138], phylogeny [139, 140], identification of coinfection, source of infection [141, 142]	The genetic diversity can be influenced by homoplasmy [143]
Whole-genome sequencing (WGS)	Transmission assessment [144], novel mutation proposal [46], strain discrimination [145], identification of source of infection [146, 147], taxonomy/phylogeny [148–151].	Higher cost compared to others

Because methods are based on different procedures that might include enzymatic digestion, PCR amplification, agarose gel analysis, sequence or fragment analysis, and fragment size estimation or counting, among others, their applicability depends on the diagnostic or typing purpose, and choice is therefore based on a combination of characteristics such as simplicity and speed of execution, cost, and differentiating power. However, one of the most important characteristics of a genotyping technique for strain differentiation is the discriminatory power, and in the case of several NTM species, PFGE presents the highest value and could in some way be considered as the reference technique [152].

Alternative fragment analysis-based procedures such as REP, AFLP, RAPD, and ERIC-PCR might be easier to perform but have the limitation that patterns and interlaboratorial comparison can be more complex. Moreover, simple variations on the DNA extraction protocol can have serious impact on the result.

One interesting application of such procedures was a study on *M. fortuitum* isolates from mammoplasty patients belonging to ITS genotype V that had indistinguishable RAPD-PCR and ERIC-PCR patterns, confirming that infections at other hospitals were caused by different *M. fortuitum* genotypes and that there was no clonal dissemination between hospitals [65]. Another study using the same tools demonstrated that ERIC-PCR has the potential to be used as a screening tool and useful for rapid epidemiological typing tools for *M. fortuitum* infections [62].

When compared to ERIC, both PFGE and RFLP demonstrated a higher resolution [60]; however, ERIC is still valid as a complementary or alternative tool for outbreak investigation, especially when working with *M. abscessus*. Compared to RAPD, however, ERIC demonstrates either a higher [62, 64, 65] or a similar discriminatory power [61].

In other studies, PFGE showed similar results as REP-PCR for *M. abscessus* typing [153, 154]. Combined with VNTR typing, PFGE demonstrated a nice tool for discrimination within *M. kansasii* [108], a species that was described as being

composed of seven subtypes [155]. Recently, six of these subspecies have been elevated to a species rank and named *M. kansasii* (former type I), *M. persicum* (II), *M. pseudokansasii* (III), *M. ostraviense* (IV), *M. innocens* (V), and *M. attenuatum* (VI) [150, 156, 157]. Even so, this organism is still presenting considerable variability as presented by division of *M. kansasii* (type I) into two *hsp65* subtypes as observed also by the overall genome organization [158]. This was confirmed in a later study adding more genomes [159], so WGS seems WGS a promising tool for future strain typing studies.

Despite being time-consuming, labor-intensive, and resource- and expertise-demanding, turning PFGE difficult to perform on a large-scale basis, it is still considered by many as the pillar method for molecular typing of NTM because of its high discriminatory power [93]. However, for some species, particular caution needs to be taken such as the case for *M. abscessus* that may present DNA degradation [152]. The subjectivity part of comparison of PFGE restriction patterns can reduce guideline focused on interpretation and using rigid algorithms but not totally eliminated [160].

The MLST technique has shown the highest sensitivity and specificity for identification to the species level of NTM [51], including discrimination of *M. abscessus* from other NTM species [97, 121]. But for typing of isolates of this species, again, PFGE was superior [161]. In another study, as expected, WGS showed a clearly higher discriminatory power in comparison with VNTR and therefore in practice the only molecular tool suitable to effectively discriminate isolates of *M. abscessus* subsp. *abscessus* and *M. abscessus* subsp. *bolletii*, with clonal groups with different drug resistance patterns and suggesting transmission between patients [145]. Interestingly, a recent study compared a large amount of clinical strains completing a total of 175 NTM species by comparing whole-genome data and developing a new MLST algorithm based on 184 genes [122]. Their MLST-based identification showed higher accuracy than conventional MLST, and besides the potential to rapidly detect pathogens, the higher amount of data might, future wise, allow the use of this combined MLST-WGS approach for strain typing.

A sometimes very severe infection of subcutaneous tissue is observed during Buruli ulcer (BU), a neglected tropical skin disease caused by *M. ulcerans* [162], and molecular tools have contributed considerably to understanding the transmission and disease reservoirs [129, 151, 163]. Among these, VNTR has demonstrated a large genetic diversity [128] also adequate for phylogenetic assessment [132] of this species. Recently, the application of WGS through a phylogeographic analysis revealed a predominant sublineage of *M. ulcerans* that arose in Central Africa and proliferated in its different regions of endemicity during the Age of Discovery [151].

A recent excellent review by Shin et al. [164] focuses on genotyping of MAC/ MAP and demonstrated that these species are mostly isolated from environmental sources such as in water and soil, therefore being the ecological niche for *M. avium* and *M. intracellulare*. Despite *M. avium* being excreted from infected animals and contaminates the environment, there seems to be no evidence for similar environmental contamination by *M. intracellulare*. Typing methods for strains from this complex can improve our understanding of estimating the infection pathway among

animals, humans, and the environment and evaluation of the treatment outcomes and the pattern of recurrence of MAC infection. The transmission of MAC species is not yet clearly defined, and together with the complex drug susceptibility pattern, more reliable and feasible genotyping methods of MAC are urgently needed,

The RGM *M. chelonae*, besides causing infections as related above, is commonly associated with skin and soft tissue infections and postsurgical infections after implants, transplants, and injections such as sclerotherapy and mesotherapy [165, 166]. Detection of source of infection is possible by molecular epidemiology studies on [56] and outbreaks by PFGE [90, 99] and/or ERIC-PCR [64]. Although considered a single species with *M. abscessus* until 1992, when *M. chelonae* was elevated to the species status, they share partial 16S rRNA signatures and are therefore still called the *M. chelonae*-*M. abscessus* group [167]. Among other phenotypical and molecular tools, RFLP was used to propose a division of this group [168] separating these species [111]. Genotyping by MLST to what were apparently particular stains of *M. chelonae* [169, 170] or of the *M. chelonae*-*M. abscessus* group [171] has also led to the identification of new (sub)species of these organisms.

Among the molecular tools, the only non-nucleic acid-based identification and typing technique for *Mycobacterium* isolates that we cover here is that based on matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS), a technique that during the last decade has turned into a timely and cost-effective identification procedure in routine microbiology laboratories [172]. In brief, a small amount of bacterial mass from a log phase culture is collected, heat inactivated, and treated with ethanol and the dried cell pellet vortexed or sonicated with beads in acetonitrile and formic acid before covering the dried extract with a special matrix. Identification is obtained both at the genus and species level between a range of 80% and 98% depending on the study [173]. The method has some limitations that have been only partly resolved. One is the impossibility to identify subspecies within the so-called *Mycobacterium* complexes that is still not possible for the MTBC. In the case of the *M. abscessus* complex, an algorithm for differentiation of the three subspecies was described [174], while the same was obtained by the use of principal component analysis [175]. Interesting also is that the formerly single species *M. kansasii* composed of seven genotypes resulted in reproducible and unique MALDI-TOF spectra that differentiated six of these [176], now separate species [150, 156, 157]. Another example of the promising evolution of this identification technique is the recently described algorithm for the differentiation of *M. intracellulare* from *M. chimaera* [177].

Two commercially systems for MALDI-TOF, each with their own *Mycobacterium* reference library, that of Bruker Biotyper with Mycobacterial Library v5.0.0 (164 species) and bioMérieux VITEK MS with v3.0 database, were recently compared and yielded similar results, although some problems were encountered in both systems for differentiation within complexes [178]. Because of the increasing number of *Mycobacterium* species and redefinition of their taxonomy, the constant need of updating of such databases to maintain accuracy of the identification is obvious [168]. Such databases have been constructed for MALDI-TOF users and can be accessed at <https://microbenet.cdc.gov>.

To our opinion, combined MALDI-TOF and genotyping analysis might be useful future wise, but the recent tentative to use the former technique alone for strain typing or lineage definition within the MTBC seems nothing but what the author's nicely called "a dream for the moment" [179].

4.4 Summary

Mycobacterium is a genus of *Actinobacteria* that are acid-fast bacilli closely related to *Corynebacteria*, *Rhodococcus*, and *Nocardia*. The genus now contains almost 200 recognized species with pure pathogenic species with best known examples *Mycobacterium tuberculosis* and *Mycobacterium leprae* and many environmental species that are sometimes also opportunistic pathogens. Mainly due to the evolution of genotyping techniques, many new species have been described during the last (two) decades, and many are to follow. Besides recognition of species, identification to the subspecies or strain level can teach us about disease transmission and bacterial population genetics and speeds up diagnosis, prediction of drug susceptibility, and evolution of disease and can therefore improve treatment. This chapter concentrates on current knowledge of strain typing of the main clinically important mycobacteria.

References

1. Lehmann KB, Neumann R (1896) Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellen bakteriologischen Diagnostik, Fift Editi
2. Atypical Acid-Fast Microorganisms | III. Chromogenic Acid-Fast Bacilli from Human Beings1, 2 | American Review of Tuberculosis. <https://www.atsjournals.org/doi/abs/10.1164/art.1935.32.4.424?journalCode=art>. Accessed 2 Sep 2020
3. Da Costa Cruz J (1938) *Mycobacterium fortuitum* um novo bacillo acidoresistance pathogenico para o homem. 1:297–301
4. Aronson JD (1926) Spontaneous tuberculosis in salt water fish. *J Infect Dis*. <https://doi.org/10.1093/infdis/39.4.315>
5. Fenner F (1950) The significance of the incubation period in infectious diseases. *Med J Aust*. <https://doi.org/10.5694/j.1326-5377.1950.tb106945.x>
6. Runyon EH (1965) Pathogenic mycobacteria. *Bibl Tuberc* 21:235–287
7. Hauduroy P (1965) Derniers aspects du monde des mycobactéries. *Masson Cie*
8. Masson AM, Prissick FH (1956) Cervical lymphadenitis in children caused by chromogenic *Mycobacteria*. *Can Med Assoc J*. 15:75(10):798–803. PMID: 13364834; PMCID: PMC1823481.
9. Runyon EH (1959) Anonymous mycobacteria in pulmonary disease. *Med Clin North Am*. [https://doi.org/10.1016/S0025-7125\(16\)34193-1](https://doi.org/10.1016/S0025-7125(16)34193-1)
10. BUHLER VB, POLLAK A (1953) Human infection with atypical acid-fast organisms; report of two cases with pathologic findings. *Am J Clin Pathol*. <https://doi.org/10.1093/ajcp/23.4.363>
11. Gruft H, Loder A, Osterhout M, Parker BD, Falkinham JO III (1979) Postulated sources of *Mycobacterium intracellulare* and *Mycobacterium scrofulaceum* infection: isolation of mycobacteria from estuaries and ocean waters. *Am Rev Respir Dis*. <https://doi.org/10.1164/ard.1979.120.6.1385>

12. Böttger EC (2013) Transmission of *M abscessus* in patients with cystic fibrosis. *Lancet*. [https://doi.org/10.1016/S0140-6736\(13\)61708-0](https://doi.org/10.1016/S0140-6736(13)61708-0)
13. Bryant JM, Grogono DM, Parkhill J, Floto RA (2013) Transmission of *M abscessus* in patients with cystic fibrosis – authors’ reply. *Lancet* 382:504
14. Bryant JM, Grogono DM, Rodriguez-Rincon D et al (2016) Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science* (80-). <https://doi.org/10.1126/science.aaf8156>
15. Gupta RS, Lo B, Son J (2018) Phylogenomics and comparative genomic studies robustly support division of the genus *Mycobacterium* into an emended genus *Mycobacterium* and four novel genera. *Front Microbiol*. <https://doi.org/10.3389/fmicb.2018.00067>
16. Tortoli E, Meehan CJ, Grottola A, Fregni Serpini G, Fabio A, Trovato A, Pecorari M, Cirillo DM (2019) Genome-based taxonomic revision detects a number of synonymous taxa in the genus *Mycobacterium*. *Infect Genet Evol*. <https://doi.org/10.1016/j.meegid.2019.103983>
17. Tuberculosis. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>. Accessed 31 Aug 2020
18. Leprosy. <https://www.who.int/news-room/fact-sheets/detail/leprosy>. Accessed 31 Aug 2020
19. Riojas MA, McGough KJ, Rider-Riojas CJ, Rastogi N, Hazbón MH (2018) Phylogenomic analysis of the species of the mycobacterium tuberculosis complex demonstrates that mycobacterium africanum, mycobacterium bovis, mycobacterium caprae, mycobacterium microti and mycobacterium pinnipedii are later heterotypic synonyms of mycob. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.002507>
20. World Health Organization (2016) The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin: policy update. World Health Organization, Geneva
21. Han XY, Seo YH, Sizer KC, Schoberle T, May GS, Spencer JS, Li W, Nair RG (2008) A new mycobacterium species causing diffuse lepromatous leprosy. *Am J Clin Pathol*. <https://doi.org/10.1309/AJCPP72FJZZRRVMM>
22. Cole ST, Brosch R, Parkhill J et al (1998) Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. *Nature* 393:537–544
23. Cole ST, Eiglmeier K, Parkhill J et al (2001) Massive gene decay in the leprosy bacillus. *Nature*. <https://doi.org/10.1038/35059006>
24. Merker M, Kohl TA, Niemann S, Supply P (2017) The evolution of strain typing in the mycobacterium tuberculosis complex. *Adv Exp Med Biol* 1019:43–78
25. Gagneux S (2018) Ecology and evolution of *Mycobacterium tuberculosis*. *Nat Rev Microbiol*. <https://doi.org/10.1038/nrmicro.2018.8>
26. Chae H, Shin SJ (2018) Importance of differential identification of *Mycobacterium tuberculosis* strains for understanding differences in their prevalence, treatment efficacy, and vaccine development. *J Microbiol*. <https://doi.org/10.1007/s12275-018-8041-3>
27. Avanzi C, Singh PTR, Suffys P (2020) Molecular epidemiology of leprosy: an update. *Inf Gen Evol* 86:104581
28. Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW (2006) Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. *Arch Dermatol*. <https://doi.org/10.1001/archderm.142.10.1287>
29. Van Dissel JT, Kuijper EJ (2009) Rapidly growing mycobacteria: emerging pathogens in cosmetic procedures of the skin. *Clin Infect Dis*. <https://doi.org/10.1086/606051>
30. Duarte RS, Lourenço MCS, Fonseca LDS et al (2009) Epidemic of postsurgical infections caused by *Mycobacterium massiliense*. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.00027-09>
31. Koh W-J (2017) Nontuberculous Mycobacteria—overview. *Microbiol Spectr*. <https://doi.org/10.1128/microbiolspec.tnmi7-0024-2016>
32. Porvaznik I, Solovič I, Mokry J (2017) Non-tuberculous mycobacteria: classification, diagnostics, and therapy. *Adv Exp Med Biol*. https://doi.org/10.1007/5584_2016_45
33. Brode SK, Daley CL, Marras TK (2014) The epidemiologic relationship between tuberculosis and nontuberculous mycobacterial disease: a systematic review. *Int J Tuberc Lung Dis*. <https://doi.org/10.5588/ijtld.14.0120>

34. Stout JE, Koh WJ, Yew WW (2016) Update on pulmonary disease due to non-tuberculous mycobacteria. *Int J Infect Dis.* <https://doi.org/10.1016/j.ijid.2016.03.006>
35. Wassilew N, Hoffmann H, Andrejak C, Lange C (2016) Pulmonary disease caused by nontuberculous mycobacteria. *Respiration.* <https://doi.org/10.1159/000445906>
36. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, Pfyffer GE, Jemmi T, Baumgartner A, Egger M (2007) *Mycobacterium avium* subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. *Lancet Infect Dis.* [https://doi.org/10.1016/S1473-3099\(07\)70211-6](https://doi.org/10.1016/S1473-3099(07)70211-6)
37. Henkle E, Winthrop KL (2015) Nontuberculous mycobacteria infections in immunosuppressed hosts. *Clin Chest Med.* <https://doi.org/10.1016/j.ccm.2014.11.002>
38. Prevots DR, Marras TK (2015) Epidemiology of human pulmonary infection with nontuberculous mycobacteria a review. *Clin Chest Med.* <https://doi.org/10.1016/j.ccm.2014.10.002>. LK – <https://utrechtuniversity.on.worldcat.org/atoztitles/link?sid=EMBASE&sid=EMBASE&issn=15578216&id=doi:10.1016%2Fj.ccm.2014.10.002&atitle=Epidemiology+of+human+pulmonary+infection+with+nontuberculous+mycobacteria+a+review&stitle=Clin.+Chest+Med.&title=Clinics+in+Chest+Medicine&volume=36&issue=1&spage=13&epage=34&aulast=Prevots&aufirst=D.+Rebecca&aunit=D.R.&aufull=Prevots+D.R.&coden=CCHMD&isbn=&pages=13-34&date=2015&aunit1=D&aunitm=R>
39. Zingue D, Bouam A, Tian RBD, Drancourt M (2018) Buruli ulcer, a prototype for ecosystem-related infection, caused by *Mycobacterium ulcerans*. *Clin Microbiol Rev.* <https://doi.org/10.1128/CMR.00045-17>
40. Tettelin H, Davidson RM, Agrawal S et al (2014) High-level relatedness among *Mycobacterium abscessus* subsp. *massiliense* strains from widely separated outbreaks. *Emerg Infect Dis.* <https://doi.org/10.3201/eid2003.131106>
41. Van Ingen J, Boeree MJ, Van Soolingen D, Mouton JW (2012) Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. *Drug Resist Updat.* <https://doi.org/10.1016/j.drug.2012.04.001>
42. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA (2004) Genes required for intrinsic multidrug resistance in *Mycobacterium avium*. *Antimicrob Agents Chemother.* <https://doi.org/10.1128/AAC.48.9.3412-3418.2004>
43. Machado D, Cannalire R, Santos Costa S, Manfroni G, Tabarrini O, Cecchetti V, Couto I, Viveiros M, Sabatini S (2016) Boosting effect of 2-phenylquinoline efflux inhibitors in combination with macrolides against *Mycobacterium smegmatis* and *Mycobacterium avium*. *ACS Infect Dis.* <https://doi.org/10.1021/acsinfecdis.5b00052>
44. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, Cambau E (2011) Assessment of clarithromycin susceptibility in strains belonging to the *Mycobacterium abscessus* group by *erm*(41) and *rrl* sequencing. *Antimicrob Agents Chemother.* <https://doi.org/10.1128/AAC.00861-10>
45. Carneiro M d S, Nunes L d S, de David SMM, Barth AL (2017) Lack of association between *rrl* and *erm*(41) mutations and clarithromycin resistance in *Mycobacterium abscessus* complex. *Mem Inst Oswaldo Cruz.* <https://doi.org/10.1590/0074-02760170080>
46. dos Santos CM, de Lima-Morales D, Crispim MN, de Souza NL, Barth AL (2020) Novel mutations in the resistome of a new sequence type (ST262) of clarithromycin resistant *Mycobacterium abscessus* subsp. *massiliense*. *J Glob Antimicrob Resist.* <https://doi.org/10.1016/j.jgar.2020.04.030>
47. Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson MC, Salfinger M, Somoskövi A, Warshauer DM, Wilson ML (2018) Practice guidelines for clinical microbiology laboratories: *Mycobacteria*. *Clin Microbiol Rev.* <https://doi.org/10.1128/CMR.00038-17>
48. Kent P, Kubica G, Kent K (1985) Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control, Atlanta
49. Springer B, Stockman L, Teschner K, Roberts GD, Bottger EC (1996) Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. *J Clin Microbiol.* <https://doi.org/10.1128/jcm.34.2.296-303.1996>

50. Telenti A, Marchesi F, Balz M, Bally F, Bottger EC, Bodmer T (1993) Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. *J Clin Microbiol*
51. Kim SH, Shin JH (2018) Identification of nontuberculous mycobacteria using multilocus sequence analysis of 16S rRNA, hsp65, and rpoB. *J Clin Lab Anal.* <https://doi.org/10.1002/jcla.22184>
52. M48Ed2 | Laboratory detection and identification of mycobacteria, 2nd edition. <https://clsi.org/standards/products/microbiology/documents/m48/>. Accessed 9 Aug 2020
53. Asimwe BB, Bagyenzi GB, Ssengooba W et al (2013) Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. *BMC Infect Dis.* <https://doi.org/10.1186/1471-2334-13-88>
54. Jönsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Qlsson C (2007) Molecular epidemiology of *Mycobacterium abscessus*, with focus on cystic fibrosis. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.02592-06>
55. Stern MJ, Ames GFL, Smith NH, Clare Robinson E, Higgins CF (1984) Repetitive extragenic palindromic sequences: a major component of the bacterial genome. *Cell.* [https://doi.org/10.1016/0092-8674\(84\)90436-7](https://doi.org/10.1016/0092-8674(84)90436-7)
56. Chroneou A, Zimmerman SK, Cook S, Willey S, Eyre-Kelly J, Zias N, Shapiro DS, Beamis JF, Craven DE (2008) Molecular typing of *Mycobacterium chelonae* isolates from a pseudo-outbreak involving an automated bronchoscope washer. *Infect Control Hosp Epidemiol.* <https://doi.org/10.1086/591451>
57. Jaubert J, Mougari F, Picot S et al (2015) A case of postoperative breast infection by *Mycobacterium fortuitum* associated with the hospital water supply. *Am J Infect Control.* <https://doi.org/10.1016/j.ajic.2014.12.023>
58. Cooksey RC, Jhung MA, Yakus MA et al (2008) Multiphasic approach reveals genetic diversity of environmental and patient isolates of *Mycobacterium mucogenicum* and *Mycobacterium phocaicum* associated with an outbreak of bacteremias at a Texas hospital. *Appl Environ Microbiol.* <https://doi.org/10.1128/AEM.02476-07>
59. Candido PHC, Nunes L d S, Marques EA et al (2014) Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients. *J Clin Microbiol* 52:2990–2997
60. Englund S (2003) IS900/ERIC-PCR as a tool to distinguish *Mycobacterium avium* subsp. paratuberculosis from closely related mycobacteria. *Vet Microbiol.* <https://doi.org/10.1016/j.vetmic.2003.08.004>
61. De Gusmão FA, Alvarenga L, Barbosa L, Sampaio J, Leão SC, Höfling-Lima AL, De Freitas D (2005) Deep stromal mycobacterial keratitis: viable bacteria after six months of treatment: case report and literature review. *Arq Bras Oftalmol.* <https://doi.org/10.1590/s0004-27492005000400024>
62. Khosravi AD, Mehrabzadeh RS, Farahani A, Jamali H (2015) Molecular identification of clinical isolates of *mycobacterium fortuitum* by random amplified polymorphic DNA (RAPD) polymerase chain reaction and ERIC PCR. *J Clin Diagnostic Res.* <https://doi.org/10.7860/JCDR/2015/15504.6909>
63. Sampaio JLM, Nassar D, De Freitas D, Höfling-Lima AL, Miyashiro K, Lopes Alberto F, Cardoso Leão S (2006) An outbreak of keratitis caused by *Mycobacterium immunogenum*. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.00656-06>
64. Sampaio JLM, Viana-Niero C, de Freitas D, Höfling-Lima AL, Leão SC (2006) Enterobacterial repetitive intergenic consensus PCR is a useful tool for typing *Mycobacterium chelonae* and *Mycobacterium abscessus* isolates. *Diagn Microbiol Infect Dis.* <https://doi.org/10.1016/j.diagmicrobio.2006.01.006>
65. Sampaio JLM, Chimara E, Ferrazoli L, da Silva Telles MA, Del Guercio VMF, Jericó ZVN, Miyashiro K, Fortaleza CMCB, Padoveze MC, Leão SC (2006) Application of four molecular typing methods for analysis of *Mycobacterium fortuitum* group strains causing post-mammoplasty infections. *Clin Microbiol Infect.* <https://doi.org/10.1111/j.1469-0691.2005.01312.x>
66. MacCannell D (2013) Bacterial strain typing. *Clin Lab Med* 33:629–650

67. García-Pedrazuela M, Frutos JM, Muñoz-Egea MC, Alcaide F, Tórtola T, Vitoria A, Cortés P, Esteban J (2015) Polyclonality among clinical strains of non-pigmented rapidly growing mycobacteria: phenotypic and genotypic differences and their potential implications. *Clin Microbiol Infect.* <https://doi.org/10.1016/j.cmi.2014.12.004>
68. Chuang AY, Tsou MH, Chang SJ, Yang LY, Shih CC, Tsai MP, Chen YL, Liu TM, Liao CH, Hsueh PR (2012) *Mycobacterium abscessus* granulomatous prostatitis. *Am J Surg Pathol.* <https://doi.org/10.1097/PAS.0b013e31823dafad>
69. Zhuo FL, Sun ZG, Li CY, Liu ZH, Cai L, Zhou C, Zhang JZ (2013) Clinical isolates of *Mycobacterium abscessus* in Guangzhou area most possibly from the environmental infection showed variable susceptibility. *Chin Med J (Engl).* <https://doi.org/10.3760/cma.j.issn.0366-6999.20122495>
70. Correa NE, Cataño JC, Mejía GI et al (2010) Outbreak of mesotherapy-associated cutaneous infections caused by *Mycobacterium chelonae* in Colombia. *Jpn J Infect Dis*
71. Zhang Q, Kennon R, Koza MA, Hulten K, Clarridge JE (2002) Pseudoepidemic due to a unique strain of *Mycobacterium szulgai*: genotypic, phenotypic, and epidemiological analysis. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.40.4.1134-1139.2002>
72. Cooksey RC, de Waard JH, Yakrus MA, Rivera I, Chopite M, Toney SR, Morlock GP, Butler WR (2004) *Mycobacterium cosmeticum* sp. nov., a novel rapidly growing species isolated from a cosmetic infection and from a nail salon. *Int J Syst Evol Microbiol.* <https://doi.org/10.1099/ijs.0.63238-0>
73. Kauppinen J, Hintikka EL, Iivanainen E, Katila ML (2001) PCR-based typing of *Mycobacterium avium* isolates in an epidemic among farmed lesser white-fronted geese (*Anser erythropus*). *Vet Microbiol.* [https://doi.org/10.1016/S0378-1135\(01\)00330-3](https://doi.org/10.1016/S0378-1135(01)00330-3)
74. Nakanaga K, Hoshino Y, Era Y, Matsumoto K, Kanazawa Y, Tomita A, Furuta M, Washizu M, Makino M, Ishii N (2011) Multiple cases of cutaneous *Mycobacterium massiliense* infection in a “hot spa” in Japan. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.00817-10>
75. Marumo K, Nakamura H, Tazawa S, Kazumi Y, Kawano R, Shirata C, Taguchi K, Kikuchi T, Nagashima G (2010) Isolation of novel mycobacteria contaminating an aquarium fish tank in a Japanese university hospital. *J Appl Microbiol.* <https://doi.org/10.1111/j.1365-2672.2010.04680.x>
76. Power EGM (1996) RAPD typing in microbiology – a technical review. *J Hosp Infect.* [https://doi.org/10.1016/S0195-6701\(96\)90106-1](https://doi.org/10.1016/S0195-6701(96)90106-1)
77. Lee MR, Tsai CJ, Hu JY, Lee SW, Ko JC, Wang HC, Yu CJ, Lee LN, Hsueh PR (2016) Acquisition of *Mycobacterium abscessus* among ventilator-dependent patients in Taiwan chronic respiratory care facilities. *Future Microbiol.* <https://doi.org/10.2217/fmb.16.6>
78. Hsueh PR, Teng LJ, Yang PC, Chen YC, Ho SW, Luh KT (1998) Recurrent catheter-related infection caused by a single clone of *Mycobacterium chelonae* with two colonial morphotypes. *J Clin Microbiol.* <https://doi.org/10.1128/jcm.36.5.1422-1424.1998>
79. Esteban J, Martín-De-Hijas NZ, Fernández AI, Fernández-Roblas R, Gadea I (2008) Epidemiology of infections due to nonpigmented rapidly growing mycobacteria diagnosed in an urban area. *Eur J Clin Microbiol Infect Dis.* <https://doi.org/10.1007/s10096-008-0521-7>
80. Esteban J, Fernández Roblas R, García Cía JI, Zamora N, Ortiz A (2007) Clinical significance and epidemiology of non-pigmented rapidly growing mycobacteria in a university hospital. *J Infect.* <https://doi.org/10.1016/j.jinf.2006.02.017>
81. Esteban J, Fernández-Roblas R, Ortiz A, García-Cía JI (2006) Pseudo-outbreak of *Mycobacterium gordonae*: usefulness of randomly amplified polymorphic DNA analysis to assess the clonality of the isolates. *Clin Microbiol Infect.* <https://doi.org/10.1111/j.1469-0691.2006.01450.x>
82. Sax H, Bloemberg G, Hasse B et al (2015) Prolonged outbreak of mycobacterium chimaera infection after open-chest heart surgery. *Clin Infect Dis.* <https://doi.org/10.1093/cid/civ198>
83. Shin JH, Lee EJ, Lee HR, Ryu SM, Kim HR, Chang CL, Kim YJ, Lee JN (2007) Prevalence of non-tuberculous mycobacteria in a hospital environment. *J Hosp Infect.* <https://doi.org/10.1016/j.jhin.2006.10.004>

84. Zhang Y, Rajagopalan M, Brown BA, Wallace RJ (1997) Randomly amplified polymorphic DNA PCR for comparison of *Mycobacterium abscessus* strains from nosocomial outbreaks. *J Clin Microbiol.* <https://doi.org/10.1128/jcm.35.12.3132-3139.1997>
85. Ramasoota P, Chansiripornchai N, Källenius G, Hoffner SE, Svenson SB (2001) Comparison of *Mycobacterium avium* complex (MAC) strains from pigs and humans in Sweden by random amplified polymorphic DNA (RAPD) using standardized reagents. *Vet Microbiol.* [https://doi.org/10.1016/S0378-1135\(00\)00302-3](https://doi.org/10.1016/S0378-1135(00)00302-3)
86. Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, Bloemberg G, Hombach M, Hasse B (2013) Prosthetic valve endocarditis and bloodstream infection due to *Mycobacterium chimaera*. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.00435-13>
87. Buijtsels PCAM, Petit PLC, Verbrugh HA, Van Belkum A, Van Soolingen D (2005) Isolation of nontuberculous mycobacteria in Zambia: eight case reports. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.43.12.6020-6026.2005>
88. Blanco-Conde S, González-Cortés C, López-Medrano R, Palacios-Gutiérrez JJ, Díez-Tascón C, Nebreda-Mayoral T, Sierra-García MJ, Rivero-Lezcano OM (2020) A strategy based on Amplified Fragment Length Polymorphism (AFLP) for routine genotyping of nontuberculous mycobacteria at the clinical laboratory. *Mol Biol Rep.* <https://doi.org/10.1007/s11033-020-05420-8>
89. Nunes L d S, Baethgen LF, Ribeiro MO, Cardoso CM, de Paris F, de David SMM, da Silva MG, Duarte RS, Barth AL (2014) Outbreaks due to *Mycobacterium abscessus* subsp. *bolletii* in southern Brazil: persistence of a single clone from 2007 to 2011. *J Med Microbiol.* <https://doi.org/10.1099/jmm.0.074906-0>
90. Kennedy BS, Bedard B, Younge M et al (2012) Outbreak of *Mycobacterium chelonae* infection associated with tattoo ink. *N Engl J Med.* <https://doi.org/10.1056/NEJMoa1205114>
91. Johnston DI, Chisty Z, Gross JE, Park SY (2016) Investigation of *Mycobacterium abscessus* outbreak among cystic fibrosis patients, Hawaii 2012. *J Hosp Infect.* <https://doi.org/10.1016/j.jhin.2016.04.015>
92. Carbonne A, Brossier F, Arnaud I, Bougmiza I, Caumes E, Meningaud JP, Dubrou S, Jarlier V, Cambau E, Astagneau P (2009) Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. *J Clin Microbiol.* <https://doi.org/10.1128/JCM.00196-09>
93. Carter KK, Lundgren I, Correll S, Schmalz T, McCarter T, Stroud J, Bruesch A, Hahn CG (2019) First United States outbreak of *Mycobacterium abscessus* hand and foot disease among children associated with a wading Pool. *J Pediatric Infect Dis Soc.* <https://doi.org/10.1093/jpids/piy036>
94. Cheng A, Sheng WH, Huang YC et al (2016) Prolonged postprocedural outbreak of *Mycobacterium massiliense* infections associated with ultrasound transmission gel. *Clin Microbiol Infect.* <https://doi.org/10.1016/j.cmi.2015.11.021>
95. Guimarães T, Chimara E, do Prado GVB, et al (2016) Pseudo-outbreak of rapidly growing mycobacteria due to *Mycobacterium abscessus* subsp *bolletii* in a digestive and respiratory endoscopy unit caused by the same clone as that of a countrywide outbreak. *Am J Infect Control* doi:<https://doi.org/10.1016/j.ajic.2016.06.019>
96. Scorzoloni L, Mengoni F, Mastroianni CM, Baldan R, Cirillo DM, De Giusti M, Marinelli L, Cottarelli A, Fattorini L, Vullo V (2016) Pseudo-outbreak of *Mycobacterium gordonae* in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization. *New Microbiol* 39(1):25–34
97. Luo L, Li B, Chu H et al (2016) Characterization of mycobacterium abscessus subtypes in Shanghai of China: drug sensitivity and bacterial epidemicity as well as clinical manifestations. *Med (United States).* <https://doi.org/10.1097/MD.0000000000002338>
98. Cardoso AM, Martins de Sousa E, Viana-Niero C, Bonfim de Bortoli F, Pereira das Neves ZC, Leão SC, Junqueira-Kipnis AP, Kipnis A (2008) Emergence of nosocomial *Mycobacterium massiliense* infection in Goiás, Brazil *Microbes Infect* doi:<https://doi.org/10.1016/j.micinf.2008.09.008>

99. Nascimento H, Viana-Niero C, Nogueira CL et al (2018) Identification of the infection source of an outbreak of mycobacterium chelonae keratitis after laser in situ keratomileusis. *Cornea*. <https://doi.org/10.1097/ICO.0000000000001423>
100. Shachor-Meyouhas Y, Geffen Y, Arad-Cohen N, Zaidman I, Ben-Barak A, Davidson S, Kassis I (2014) Mycobacterium phocaicum bacteremia: an emerging infection in pediatric hematology-oncology patients. *Pediatr Infect Dis J*. <https://doi.org/10.1097/INF.0000000000000477>
101. Fernandes Garcia de Carvalho N, Rodrigues Mestrinari AC, Brandão A et al (2018) Hospital bronchoscopy-related pseudo-outbreak caused by a circulating Mycobacterium abscessus subsp. massiliense. *J Hosp Infect*. <https://doi.org/10.1016/j.jhin.2018.07.043>
102. Abalain-Colloc ML, Guillem D, Saláun M, Gouriou S, Vincent V, Picard B (2003) Mycobacterium szulgai isolated from a patient, a tropical fish and aquarium water. *Eur J Clin Microbiol Infect Dis*. <https://doi.org/10.1007/s10096-003-1036-x>
103. Rodriguez JM, Xie YL, Winthrop KL, Schafer S, Sehdev P, Solomon J, Jensen B, Toney NC, Lewis PF (2013) Mycobacterium chelonae facial infections following injection of dermal filler. *Aesthetic Surg J*. <https://doi.org/10.1177/1090820X12471944>
104. Wu TS, Yang CH, Brown-Elliott BA, Chao AS, Leu HS, Wu TL, Lin CS, Griffith DE, Chiu CH (2016) Postcesarean section wound infection caused by Mycobacterium massiliense. *J Microbiol Immunol Infect*. <https://doi.org/10.1016/j.jmii.2015.06.010>
105. Boyle DP, Zembower TR, Qi C (2016) Relapse versus reinfection of mycobacterium avium complex pulmonary disease: patient characteristics and macrolide susceptibility. *Ann Am Thorac Soc*. <https://doi.org/10.1513/AnnalsATS.201605-344BC>
106. Tsao SM, Sen LK, Liao HH, Huang TL, Shen GH, Tsao Thomas CY, Lee YT (2014) The clinical management of cesarean section-acquired Mycobacterium abscessus surgical site infections. *J Infect Dev Ctries*. <https://doi.org/10.3855/jidc.3821>
107. Zhang Y, Yakrus MA, Graviss EA, Williams-Bouyer N, Turenne C, Kabani A, Wallace RJ (2004) Pulsed-field gel electrophoresis study of Mycobacterium abscessus isolates previously affected by DNA degradation. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.42.12.5582-5587.2004>
108. Bakula Z, Brzostek A, Borówka P et al (2018) Molecular typing of Mycobacterium kansasii using pulsed-field gel electrophoresis and a newly designed variable-number tandem repeat analysis. *Sci Rep*. <https://doi.org/10.1038/s41598-018-21562-z>
109. Hoefsloot W, Van Ingen J, Andrejak C et al (2013) The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J* 42:1604–1613
110. O'Driscoll C, Konjek J, Heym B et al (2016) Molecular epidemiology of Mycobacterium abscessus complex isolates in Ireland. *J Cyst Fibros*. <https://doi.org/10.1016/j.jcf.2015.05.007>
111. Khan IUH, Selvaraju SB, Yadav JS (2005) Occurrence and characterization of multiple novel genotypes of Mycobacterium immunogenum and Mycobacterium chelonae in metalworking fluids. *FEMS Microbiol Ecol*. <https://doi.org/10.1016/j.femsec.2005.04.009>
112. Thomson R, Tolson C, Huygens F, Hargreaves M (2014) Strain variation amongst clinical and potable water isolates of *M. kansasii* using automated repetitive unit PCR. *Int J Med Microbiol*. <https://doi.org/10.1016/j.ijmm.2014.02.004>
113. Kobashi Y, Yoshida K, Niki Y, Oka M (2006) Sibling cases of Mycobacterium avium complex disease associated with hematological disease. *J Infect Chemother*. <https://doi.org/10.1007/s10156-006-0461-z>
114. da Costa ARF, Falkinham JO III, Lopes ML, Barretto AR, Felicio JS, Sales LHM, Bahia JRC, Conceição EC, Lima KVB (2013) Occurrence of nontuberculous mycobacterial pulmonary infection in an endemic area of tuberculosis. *PLoS Negl Trop Dis*. <https://doi.org/10.1371/journal.pntd.0002340>
115. Huang CC, Chen JH, Hu ST, Chiou CS, Huang WC, Hsu JY, Lu JJ, Shen GH (2012) Combined rpoB duplex PCR and hsp65 PCR restriction fragment length polymorphism with capillary electrophoresis as an effective algorithm for identification of Mycobacterial species from clinical isolates. *BMC Microbiol*. <https://doi.org/10.1186/1471-2180-12-137>

116. Salmanzadeh S, Honarvar N, Goodarzi H, Khosravi AD, Nashibi R, Serajian AA, Hashemzadeh M (2014) Chronic mycobacterial meningitis due to *Mycobacterium chelonae*: a case report. *Int J Infect Dis*. <https://doi.org/10.1016/j.ijid.2014.04.004>
117. Bruijnesteijn Van Coppenraet LES, De Haas PEW, Lindeboom JA, Kuijper EJ, Van Soolingen D (2008) Lymphadenitis in children is caused by *Mycobacterium avium* hominissuis and not related to “bird tuberculosis”. *Eur J Clin Microbiol Infect Dis*. <https://doi.org/10.1007/s10096-007-0440-z>
118. Zhang X, Liu W, Liu W, Jiang H, Zong W, Zhang G, Jin P, Wang H (2015) Cutaneous infections caused by rapidly growing mycobacteria: case reports and review of clinical and laboratory aspects. *Acta Derm Venereol*. <https://doi.org/10.2340/00015555-2105>
119. Mortazavi Z, Bahrmand A, Sakhaee F, Doust RH, Vaziri F, Siadat SD, Fateh A (2019) Evaluating the clinical significance of nontuberculous mycobacteria isolated from respiratory samples in Iran: an often overlooked disease. *Infect Drug Resist*. <https://doi.org/10.2147/IDR.S214181>
120. Aravindhavan V, Sulochana S, Narayanan S, Paramasivam CN, Narayanan PR (2007) Identification & differentiation of *Mycobacterium avium* & *M. intracellulare* by PCR-RFLP assay using the *groES* gene. *Indian J Med Res* 126(6):575–579
121. Kim BJ, Kim GN, Kim BR, Shim TS, Kook YH, Kim BJ (2019) New *Mycobacteroides abscessus* subsp. *massiliense* strains with recombinant *hsp65* gene laterally transferred from *Mycobacteroides abscessus* subsp. *abscessus*: potential for misidentification of *M. abscessus* strains with the *hsp65*-based method. *PLoS One*. <https://doi.org/10.1371/journal.pone.0220312>
122. Matsumoto Y, Kinjo T, Motooka D, Nabeya D, Jung N, Uechi K, Horii T, Iida T, Fujita J, Nakamura S (2019) Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles. *Emerg Microbes Infect*. <https://doi.org/10.1080/22221751.2019.1637702>
123. Hirama T, Marchand-Austin A, Ma J, Alexander DC, Brode SK, Marras TK, Jamieson FB (2018) *Mycobacterium xenopi* genotype associated with clinical phenotype in lung disease. *Lung*. <https://doi.org/10.1007/s00408-018-0087-9>
124. Kham-ngam I, Chetchotisakd P, Ananta P, Chaimanee P, Reechaipichitkul W, Lulitanond V, Namwat W, Faksri K (2019) Differentiation between persistent infection/colonization and re-infection/re-colonization of *Mycobacterium abscessus* isolated from patients in Northeast Thailand. *Infect Genet Evol*. <https://doi.org/10.1016/j.meegid.2018.12.001>
125. Lee SY, Kim BJ, Kim H et al (2016) *Mycobacterium paraintracellulare* sp. Nov., for the genotype INT-1 of *Mycobacterium intracellulare*. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.001158>
126. Sun Z, Li W, Xu S, Huang H (2016) The discovery, function and development of the variable number tandem repeats in different *Mycobacterium* species. *Crit Rev Microbiol*. <https://doi.org/10.3109/1040841X.2015.1022506>
127. Yoshida S, Tsuyuguchi K, Kobayashi T, Tomita M, Inoue Y, Hayashi S, Suzuki K (2018) Association between sequevar and antibiotic treatment outcome in patients with *Mycobacterium abscessus* complex infections in Japan. *J Med Microbiol*. <https://doi.org/10.1099/jmm.0.000661>
128. Dassi C, Mossi L, Narh CA, Quaye C, Konan DO, Djaman JA, Bonfoh B (2017) Distribution and risk of mycolactone-producing mycobacteria transmission within Buruli ulcer endemic communities in Côte d’Ivoire. *Trop Med Infect Dis*. <https://doi.org/10.3390/tropicalmed2010003>
129. Djouaka R, Zeukeng F, Bigoga JD et al (2018) Domestic animals infected with *Mycobacterium ulcerans*—implications for transmission to humans. *PLoS Negl Trop Dis*. <https://doi.org/10.1371/journal.pntd.0006572>
130. Kusuki M, Osawa K, Arikawa K et al (2018) Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the *Mycobacterium abscessus* complex in Japan by variable number tandem repeat analysis. *Diagn Microbiol Infect Dis*. <https://doi.org/10.1016/j.diagmicrobio.2018.02.008>
131. Imperiale BR, Moyano RD, Di Giulio AB, Romero MA, Alvarado Pinedo MF, Santangelo MP, Travería GE, Morcillo NS, Romano MI (2017) Genetic diversity of *Mycobacterium*

- avium complex strains isolated in Argentina by MIRU-VNTR. *Epidemiol Infect.* <https://doi.org/10.1017/S0950268817000139>
132. Reynaud Y, Millet J, Couvin D, Rastogi N, Brown C, Couppié P, Legrand E (2015) Heterogeneity among *Mycobacterium ulcerans* from French Guiana revealed by multilocus variable number tandem repeat analysis (MLVA). *PLoS One.* <https://doi.org/10.1371/journal.pone.0118597>
 133. Zumárraga MJ, Arriaga C, Barandiaran S et al (2013) Understanding the relationship between *Mycobacterium bovis* spoligotypes from cattle in Latin American countries. *Res Vet Sci* 94:9–21
 134. Genua F, Menichini M, Lari N, Rindi L (2018) Genotyping and clarithromycin susceptibility testing of *Mycobacterium avium* subsp. *hominissuis* isolated in Tuscany, Italy. *Infect Genet Evol.* <https://doi.org/10.1016/j.meegid.2018.07.032>
 135. Zhao X, Wang Y, Pang Y (2014) Antimicrobial susceptibility and molecular characterization of *Mycobacterium intracellulare* in China. *Infect Genet Evol.* <https://doi.org/10.1016/j.meegid.2014.07.032>
 136. Zheng HW, Pang Y, He GX, Song YY, Zhao YL (2017) Comparing the genotype and drug susceptibilities between *Mycobacterium avium* and *Mycobacterium intracellulare* in China. *Biomed Environ Sci.* <https://doi.org/10.3967/bes2017.068>
 137. Yamaba Y, Ito Y, Suzuki K et al (2019) Moxifloxacin resistance and genotyping of *Mycobacterium avium* and *Mycobacterium intracellulare* isolates in Japan. *J Infect Chemother.* <https://doi.org/10.1016/j.jiac.2019.05.028>
 138. Chen K, Zhang Y, Peng Y (2017) Variable-number tandem repeat markers for *mycobacterium intracellulare* genotyping: comparison to the 16s rRNA gene sequencing. *J Infect Dev Ctries.* <https://doi.org/10.3855/jidc.7669>
 139. Yano H, Suzuki H, Maruyama F, Iwamoto T (2019) The recombination-cold region as an epidemiological marker of recombinogenic opportunistic pathogen *Mycobacterium avium*. *BMC Genomics.* <https://doi.org/10.1186/s12864-019-6078-2>
 140. Ichikawa K, van Ingen J, Koh WJ et al (2015) Genetic diversity of clinical *Mycobacterium avium* subsp. *hominissuis* and *Mycobacterium intracellulare* isolates causing pulmonary diseases recovered from different geographical regions. *Infect Genet Evol.* <https://doi.org/10.1016/j.meegid.2015.09.029>
 141. Barandiaran S, Pérez AM, Gioffré AK, Martínez Vivot M, Cataldi AA, Zumárraga MJ (2015) Tuberculosis in swine co-infected with *Mycobacterium avium* subsp. *Hominissuis* and *Mycobacterium bovis* in a cluster from Argentina. *Epidemiol Infect.* <https://doi.org/10.1017/S095026881400332X>
 142. Narh CA, Mosi L, Quaye C, Dassi C, Konan DO, Tay SCK, de Souza DK, Boakye DA, Bonfoh B (2015) Source tracking *Mycobacterium ulcerans* infections in the Ashanti Region, Ghana. *PLoS Negl Trop Dis.* <https://doi.org/10.1371/journal.pntd.0003437>
 143. Kalvisa A, Tsirogiannis C, Silamikelis I, Skenders G, Broka L, Zirmitsis A, Jansone I, Ranka R (2016) MIRU-VNTR genotype diversity and indications of homoplasmy in *M. avium* strains isolated from humans and slaughter pigs in Latvia. *Infect Genet Evol.* <https://doi.org/10.1016/j.meegid.2016.05.013>
 144. Yoon JK, Kim TS, Kim J II, Yim JJ (2020) Whole genome sequencing of Nontuberculous *Mycobacterium* (NTM) isolates from sputum specimens of co-habiting patients with NTM pulmonary disease and NTM isolates from their environment. *BMC Genomics* doi:<https://doi.org/10.1186/s12864-020-6738-2>
 145. Trovato A, Baldan R, Costa D, Simonetti TM, Cirillo DM, Tortoli E (2017) Molecular typing of *Mycobacterium abscessus* isolated from cystic fibrosis patients. *Int J Mycobacteriol.* https://doi.org/10.4103/ijmy.ijmy_33_17
 146. Hasan NA, Epperson LE, Lawsin A et al (2019) Genomic analysis of cardiac surgery-associated *Mycobacterium chimaera* infections, United States. *Emerg Infect Dis.* <https://doi.org/10.3201/eid2503.181282>
 147. Coudereau C, Besnard A, Robbe-Saule M et al (2020) Stable and local reservoirs of *mycobacterium ulcerans* inferred from the nonrandom distribution of bacterial genotypes, Benin. *Emerg Infect Dis.* <https://doi.org/10.3201/eid2603.190573>

148. Lande L, Alexander DC, Wallace RJ et al (2019) *Mycobacterium avium* in community and household water, suburban Philadelphia, Pennsylvania, USA, 2010-2012. *Emerg Infect Dis*. <https://doi.org/10.3201/eid2503.180336>
149. Turenne CY (2019) Nontuberculous mycobacteria: insights on taxonomy and evolution. *Infect Genet Evol*. <https://doi.org/10.1016/j.meegid.2019.01.017>
150. Jagielski T, Borówka P, Bakula Z et al (2020) Genomic insights into the *Mycobacterium kansasii* complex: an update. *Front Microbiol*. <https://doi.org/10.3389/fmicb.2019.02918>
151. Vandellannoote K, Phanuz DM, Kibadi K et al (2019) *Mycobacterium ulcerans* population genomics to inform on the spread of Buruli ulcer across Central Africa. *mSphere*. <https://doi.org/10.1128/msphere.00472-18>
152. Wallace RJ, Zhang Y, Brown BA, Fraser V, Mazurek GH, Maloney S (1993) DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of *Mycobacterium chelonae* and *Mycobacterium abscessus*. *J Clin Microbiol*. <https://doi.org/10.1128/jcm.31.10.2697-2701.1993>
153. Zelazny AM, Root JM, Shea YR et al (2009) Cohort study of molecular identification and typing of *Mycobacterium abscessus*, *Mycobacterium massiliense*, and *Mycobacterium boletii*. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.01688-08>
154. Aitken ML, Limaye A, Pottinger P et al (2012) Respiratory outbreak of *Mycobacterium abscessus* subspecies *massiliense* in a lung transplant and cystic fibrosis center. *Am J Respir Crit Care Med*. <https://doi.org/10.1164/ajrccm.185.2.231>
155. Taillard C, Greub G, Weber R et al (2003) Clinical implications of *Mycobacterium kansasii* species heterogeneity: Swiss national survey. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.41.3.1240-1244.2003>
156. Tagini F, Aeby S, Bertelli C, Droz S, Casanova C, Prod'Hom G, Jaton K, Greub G (2019) Phylogenomics reveal that *mycobacterium kansasii* subtypes are species-level lineages. Description of *mycobacterium pseudokansasii* sp. nov., *mycobacterium innocens* sp. nov. and *mycobacterium attenuatum* sp. nov. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.003378>
157. Shahraki AH, Trovato A, Mirsaedi M, Borroni E, Heidarieh P, Hashemzadeh M, Shahbazi N, Cirillo DM, Tortoli E (2017) *Mycobacterium persicum* sp. Nov., a novel species closely related to *mycobacterium kansasii* and *mycobacterium gastri*. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.001862>
158. Machado E, Vasconcellos SEG, Cerdeira C et al (2018) Whole genome sequence of *Mycobacterium kansasii* isolates of the genotype 1 from Brazilian patients with pulmonary disease demonstrates considerable heterogeneity. *Mem Inst Oswaldo Cruz*. <https://doi.org/10.1590/0074-02760180085>
159. Guan Q, Ummels R, Ben-Rached F, Alzahid Y, Amini MS, Adroub SA, van Ingen J, Bitter W, Abdallah AM, Pain A (2020) Comparative genomic and transcriptomic analyses of *Mycobacterium kansasii* subtypes provide new insights into their pathogenicity and taxonomy. *Front Cell Infect Microbiol*. <https://doi.org/10.3389/fcimb.2020.00122>
160. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol*. <https://doi.org/10.1128/jcm.33.9.2233-2239.1995>
161. Machado GE, Matsumoto CK, Chimara E et al (2014) Multilocus sequence typing scheme versus pulsed-field gel electrophoresis for typing *Mycobacterium abscessus* isolates. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.00688-14>
162. Walsh DS, Portaels F, Meyers WM (2008) Buruli ulcer (*Mycobacterium ulcerans* infection). *Trans R Soc Trop Med Hyg* 102:969-978
163. Qi W, Käser M, Röltgen K, Yeboah-Manu D, Pluschke G (2009) Genomic diversity and evolution of *Mycobacterium ulcerans* revealed by next-generation sequencing. *PLoS Pathog* 5:e1000580

164. Shin JI, Shin SJ, Shin MK (2020) Differential genotyping of *Mycobacterium avium* complex and its implications in clinical and environmental epidemiology. *Microorganisms*. <https://doi.org/10.3390/microorganisms8010098>
165. Cooper JF (1989) *Mycobacterium chelonae*. *Infect Dis Newsl* 8:70–71
166. Akram SM, Rathish B, Saleh D (2020) *Mycobacterium Chelonae*. *StatPearls Publ*. <https://www.ncbi.nlm.nih.gov/books/NBK430806/>. Accessed 8 Sep 2020
167. Williams KJ, Ling CL, Jenkins C, Gillespie SH, McHugh TD (2007) A paradigm for the molecular identification of *Mycobacterium* species in a routine diagnostic laboratory. *J Med Microbiol*. <https://doi.org/10.1099/jmm.0.46855-0>
168. Leao SC, Tortoli E, Viana-Niero C, Ueki SYM, Lima KVB, Lopes ML, Yubero J, Menendez MC, Garcia MJ (2009) Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the *Mycobacterium chelonae*-*M. abscessus* group is needed. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.00808-09>
169. Kim BJ, Kim BR, Jeong J, Lim JH, Park SH, Lee SH, Kim CK, Kook YH, Kim BJ (2018) A description of *mycobacterium chelonae* subsp. *gwanakae* subsp. nov., a rapidly growing mycobacterium with a smooth colony phenotype due to glycopeptidolipids. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.003056>
170. Kim BJ, Kim GN, Kim BR et al (2017) Description of *mycobacterium chelonae* subsp. *Bovis* subsp. nov., isolated from cattle (*bos taurus coreanae*), emended description of *mycobacterium chelonae* and creation of *mycobacterium chelonae* subsp. *chelonae* subsp. nov. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.002217>
171. Nogueira CL, Whipps CM, Matsumoto CK et al (2015) *Mycobacterium saopaulense* sp. Nov., a rapidly growing mycobacterium closely related to members of the *mycobacterium chelonae*-*mycobacterium abscessus* group. *Int J Syst Evol Microbiol*. <https://doi.org/10.1099/ijsem.0.000590>
172. Rodríguez-Sánchez B, Cercenado E, Coste AT, Greub G (2019) Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018. *Eurosurveillance*. <https://doi.org/10.2807/1560-7917.ES.2019.24.4.1800193>
173. Alcaide F, Amlerová J, Bou G et al (2018) How to: identify non-tuberculous *Mycobacterium* species using MALDI-TOF mass spectrometry. *Clin Microbiol Infect*. <https://doi.org/10.1016/j.cmi.2017.11.012>
174. Fangous MS, Mougari F, Gouriou S, Calvez E, Raskine L, Cambau E, Payan C, Héry-Arnaud G (2014) Classification algorithm for subspecies identification within the *Mycobacterium abscessus* species, based on matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol*. <https://doi.org/10.1128/JCM.00788-14>
175. Kehrmann J, Wessel S, Murali R, Hampel A, Bange FC, Buer J, Mosel F (2016) Principal component analysis of MALDI TOF MS mass spectra separates *M. abscessus* (*sensu stricto*) from *M. massiliense* isolates. *BMC Microbiol*. <https://doi.org/10.1186/s12866-016-0636-4>
176. Murugaiyan J, Lewin A, Kamal E et al (2018) MALDI spectra database for rapid discrimination and subtyping of *Mycobacterium kansasii*. *Front Microbiol*. <https://doi.org/10.3389/fmicb.2018.00587>
177. Pranada AB, Witt E, Bienia M, Kostrzewa M, Timke M (2017) Accurate differentiation of *mycobacterium chimaera* from *mycobacterium intracellulare* by MALDI-TOF MS analysis. *J Med Microbiol*. <https://doi.org/10.1099/jmm.0.000469>
178. Brown-Elliott BA, Fritsche TR, Olson BJ, Vasireddy S, Vasireddy R, Iakhiaeva E, Alame D, Wallace RJ, Branda JA (2019) Comparison of two commercial matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for identification of nontuberculous mycobacteria. *Am J Clin Pathol* 152:527–536
179. O'Connor JA, Corcoran GD, O'Reilly B, O'Mahony J, Lucey B (2020) Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for investigation of *mycobacterium tuberculosis* complex outbreaks: a type dream? *J Clin Microbiol*. <https://doi.org/10.1128/JCM.02077-19>